February 13, 2018
New international practice guidelines for using tamoxifen to treat breast cancer
An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium (CPIC) published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics. Tamoxifen is a hormonal agent used for the prevention and treatment of premenopausal and postmenopausal breast cancer that is estrogen receptor positive. […]
Tags: #CIMCon18, #clinical guidelines, #Clinical Pharmacogenetics Implementation Consortium, #CYP2D6 geneotype, #estrogen receptor positive breast cancer, #tamoxifen, #targeted therapies, breast cancer, center for individualized medicine, DNA Sequencing, Dr. Matthew Goetz, Genetic Testing